INTRODUCTION
The use of alpha emitters for cancer therapy has two distinct advantages over conventional therapies. The short range of alpha radiation in human tissue corresponding to only a few cell diameters (< 0.1 mm) allows the selective killing of targeted cancer cells while sparing surrounding healthy tissue. At the same time, the high energy of alpha radiation of several MeV and its associated high linear energy transfer leads to highly effective cell killing via DNA double strand and DNA cluster breaks, which are largely independent of cell cycle and oxygenation status [1, 2] . Consequently, alpha radiation can kill cells which otherwise exhibit resistance to treatment with beta-or gammairradiation or chemotherapeutic drugs, and can thus offer a therapeutic option for patients resistant to conventional therapies [3] [4] [5] . Only few alpha-emitting radionuclides are suitable for clinical application in targeted alpha therapy [6] . With the exception of the approved bone-seeking alpha emitter 223 Ra, by far most clinical experience is available with 225 Ac (T 1/2 = 9.9 d) and its short-lived daughter nuclide 213 Bi (T 1/2 = 46 min). Here we review methods for the production of 225 Ac / 213 Bi based on radiochemical extraction from 229 Th sources as well as accelerator driven processes and give an overview on the existing clinical experience with special focus on recent results in the treatment of bladder cancer, glioma, neuroendocrine tumors and prostate cancer.
*Address correspondence to this author at the European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany; Tel: 497247951248; E-mail: alfred.morgenstern@ec.europa.eu 225 AC AND 213 BI 225 Ac is a relatively long-lived alpha emitter with a halflife of 9.9 days [7] . It decays via a cascade of six short-lived radionuclide daughters to near stable 209 Bi (T 1/2 = 1.9x10 19 y) ( Fig. 1) [8] . The predominant decay path of 225 Ac yields net four alpha particles with energies ranging from 5.8 to 8.4 MeV and associated tissue ranges of 47 to 85 m [1] . In addition, the cascade includes two beta disintegrations of 1.6 and 0.6 MeV maximum energy. Gamma co-emissions useful for in vivo imaging are generated in the 225 Ac decay path from the disintegration of 221 Fr (218 keV, 11.6% emission probability) and 213 Bi (440 keV, 26.1% emission probability). Its long half-life and the multiple alpha particles generated in the decay chain render 225 Ac a particularly cytotoxic radionuclide. 213 Bi is a mixed alpha/beta emitter with a half-life of 46 min. It mainly decays via beta -emission to the ultra shortlived, pure alpha emitter 213 Po (T 1/2 = 4.2 s, E = 8.375 MeV) with a branching ratio of 97.8% (Fig. 1) . The remaining 2.2 % of 213 Bi decays leading to 209 Tl via alpha particle emission (E = 5.549 MeV, 0.16%, E = 5. 213 Po has a path length of 85 m in human tissue. It is contributing more than 98% of the alpha particle energy emitted per disintegration of 213 Bi and can therefore be considered as mainly responsible for its cytotoxic effects. With 92.7 % the majority of the total particle energy emitted per disintegration of 213 Bi originates from alpha decay, while only 7.3 % of decay energy is contributed by beta particle emission, including the decay of 209 Pb [1] . The decay of 213 Bi is accompanied by the emission of a 440 keV photon (emission probability of 26.1%) that can be detected using SPECT gamma cameras equipped with commercially available high energy collimators, allowing the monitoring of 213 Bi-biodistribution and the conduction of pharmacokinetic and dosimetric studies.
DECAY CHARACTERISTICS OF

PRODUCTION OF
225 AC AND 213 BI
Radiochemical Extraction from 229 Th
For more than two decades, the main process utilized for the production of 225 Ac and 213 Bi has been based on radiochemical extraction from 229 Th (T 1/2 = 7,317 y) [9] sources originating from the decay of fissile 233 U. To date, all clinical tests and the vast majority of pre-clinical research with 225 Ac and 213 Bi have been conducted using 225 Ac / 213 Bi obtained from the decay of 229 Th. Sources of 229 Th allowing the production of clinically relevant activities of 225 Ac / 213 Bi are available at the Directorate for Nuclear Safety and Security of the Joint Research Centre (JRC) of the European Commission in Karlsruhe, Germany (formerly known as Institute for Transuranium Elements) [10, 11] , Oak Ridge National Laboratory (ORNL), USA [12] and at the Institute of Physics and Power Engineering (IPPE) in Obninsk, Russia [13] . The 229 Th sources have been obtained by separation from aged, fissile 233 U originally produced by neutron irradiation of natural 232 Th. More recently, the isolation of a 229 Th source has also been reported from Canadian Nuclear Laboratories [14] .
The production of 225 Ac from 229 Th at JRC Karlsruhe and ORNL has been described in detail in [10] [11] [12] and in a recent review [15] . JRC has been the first laboratory to provide 225 Ac / 213 Bi to clinical partners in the mid-1990's and since then, has produced approximately 13 GBq 225 Ac annually for preclinical research and clinical testing performed at JRC Karlsruhe or in collaboration with a wide network of clinical partners. The maximum annual production of 225 Ac at ORNL is approximately 33 GBq, while IPPE has reported a production of 22 GBq per year [13] . 225 Ac produced at JRC Karlsruhe and ORNL has been extensively applied for patient treatment and found safe for administration to humans. Direct clinical application of 225 Ac produced at IPPE has not been reported to date.
Overall the current worldwide production of 225 Ac from 229 Th amounts to approximately 68 GBq per year. This level of supply allows the conduction of pre-clinical studies and is sufficient for the treatment of several hundreds of patients per year, in particular when 225 Ac-labeled ligands are used where administered activities typically range from 4 -50 MBq per therapeutic dose. However, the current supply of 225 Ac is certainly insufficient for widespread use and routine application in hospitals worldwide. Consequently, a variety of alternative methods for large-scale production of 225 Ac have been investigated.
Accelerator-Based Routes
Alternative ways of producing 225 Ac / 213 Bi, including the irradiation of 226 Ra targets using neutrons, protons, deuterons or gamma-rays and the irradiation of 232 Th targets with highly energetic protons have been investigated [16] , but have not yet been implemented for a regular supply of 225 Ac / 213 Bi.
Among these routes, the production of 225 Ac by proton irradiation of 226 Ra targets in a cyclotron through the reaction 225 Ac is currently the most promising process for large-scale production of 225 Ac. The maximum cross-section for the nuclear reaction has been reported as 7.1 x 10 2 ± 68 mb at 16.8 MeV proton energy [17] . The production can be performed with high yields in a cost-effective manner in medium-sized cyclotrons at proton energies below 20 MeV. An important advantage of the process is that no other longlived actinium isotopes such as 227 Ac (T 1/2 = 21.8 y) are coproduced, and chemical purification of the irradiated targets yields 225 Ac of high isotopic purity. Co-production of shortlived 226 Ac (T 1/2 = 29 h) and 224 Ac (T 1/2 = 2.9 h) according to the reactions, 226 Ra(p,n) 226 Ac and 226 Ra(p,3n) 224 Ac can be minimized through selection of appropriate proton energies. Furthermore, these short-lived actinium isotopes decay to low levels during the time required for target cooling and reprocessing. Although the handling of cyclotron targets made from 226 Ra is technically demanding, the production of 225 Ac via proton irradiation of 226 Ra is the method of choice for large-scale, cost-effective production and can be expected to provide the amounts of high purity 225 Ac required for widespread application in the mid-term future.
An alternative accelerator driven method for the production of 225 Ac has been developed in recent years based on the irradiation of 232 Th targets with high energy protons [18] [19] [20] [21] [22] [23] . It has been demonstrated that spallation of 232 Th with high energetic protons available at large accelerators can produce significant amounts of 225 Ac and production yields in the range of several GBq have been reported for irradiations using intense proton beams and lasting 10 days [20, 21] . The spallation of 232 Th simultaneously leads to a significant coproduction of radionuclidic impurities that must be removed through appropriate multi-step chemical separation steps [24] [25] [26] . However, the main disadvantage of the 232 Th based spallation process is the co-production of long-lived 227 Ac (T 1/2 = 21.8 y) at activity levels of 0.1 to 0.2% relative to the activity of 225 Ac at end of bombardment [22] . Since 225 Ac and 227 Ac isotopes cannot be chemically separated, the implications of the 227 Ac impurity for the clinical application of the 225 Ac product have to be carefully evaluated. Initial studies investigating the potential toxicity and dosimetric aspects of the 227 Ac impurity indicate that the consequences for patient safety might be acceptable [27] . However, issues related to the safe handling and disposal of long-lived 227 Ac in hospitals might compromise the clinical acceptance of the product and still have to be addressed.
4.
225 AC / 213 BI RADIONUCLIDE GENERATORS AND LABELLING CHEMISTRY OF 225 AC AND 213 BI 225 Ac / 213 Bi generators have been recently reviewed in detail [28] . Briefly, 225 Ac / 213 Bi generators based on AG MP-50 cation exchange resin are most established and have been used for all patient studies with 213 Bi to date. JRC Karlsruhe has developed a high activity generator system that allows reliable operation of the generator when loaded with activities up to 4 GBq 225 Ac [29] . A key feature of this generator is the homogeneous distribution of 225 Ac activity over approximately two-thirds of the generator resin in order to minimize radiolytic degradation of the organic resin and to assure reliable operation over several weeks. The generator has been successfully used for the preparation of therapeutic doses of up to 2.3 GBq 213 Bi-Substance P analogue (activity at the time of injection) for locoregional treatment of brain tumors.
The labelling chemistry of 213 Bi is well established. 213 Bi can be stably linked to biomolecules via derivatives of DTPA (diethylene triamine pentaacetic acid) or DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid).
Derivatives of the open-chain chelating ligand DTPA are particularly suitable for 213 Bi-labelling of antibodies due to their fast complexation kinetics at room temperature. As Bismuth(III) complexes of the pre-organised derivative 2-diamine-N,N,N',N" ,N"-pentaacetic acid) are exhibiting very high in vivo stability [30, 31] , CHX-A''-DTPA is the chelate of choice for 213 Bi-labelling of antibodies. Optimized protocols for 213 Bi labelling of antibodies in clinical settings allow the synthesis, sterile filtration and quality control of therapeutic doses within 15 min after end of generator elution [32] .
Complexes of Bi(III) with the highly pre-organized, octadentate DOTA ligand are kinetically inert and also exhibit high stability in vivo [33, 34] . A synthesis protocol based on microwave heating to 95 °C at pH 9 was developed that allows rapid 213 Bi-labelling of DOTA-chelated peptides with radiochemical yields exceeding 99% and specific activities exceeding 50 MBq/nmol within less than 5 min reaction time [35] . Using this robust synthesis scheme, DOTA chelated peptides developed for peptide receptor radiotherapy, such as DOTA-Substance P targeting the neurokinin-1 receptor and the widely used somatostatin-analogs (e.g. DO-TATOC, DOTATATE) can be labelled with 213 Bi in a straightforward manner.
Labeling of biomolecules with 225 Ac(III) is also typically performed via the DOTA chelate. Rapid synthesis can be performed via microwave heating to 95 °C for 5 min at pH 9 with radiochemical yields exceeding 99% at specific activities of 0.1 MBq /nmol [5] . For labelling of heat sensitive biomolecules at temperatures not exceeding 40 °C, slightly longer reaction times are required [36] . Recently, the 18-membered macrocycle N,N -bis[(6-carboxy-2-pyridil)methyl]-4,13-diaza-18-crown-6 (H 2 macropa) has been investigated for chelation of 225 Ac [37] . H 2 macropa was found to rapidly bind kBq activities of 225 Ac at room temperature leading to a complex with high in vivo stability. Therefore H 2 macropa might offer a valuable alternative for 225 Ac labelling of heat sensitive biomolecules. These highly promising results still need to be confirmed in further studies with therapeutic activities of 225 Ac in the MBq range. 225 AC AND 213 BI Table 1 gives an overview of the current clinical experience with 225 Ac and 213 Bi. To date more than 500 patients have received 225 Ac-and 213 Bi-labeled radioconjugates for therapy of leukemia [38] [39] [40] , Non-Hodgkins Lymphoma [41] , malignant melanoma [42] [43] [44] , bladder cancer [32, 45] , glioma [46] [47] [48] , neuroendocrine tumors [4, 49] , and prostate cancer [5, 50, 51] . All clinical tests listed in Table 1 have been conducted using 225 Ac or 225 Ac / 213 Bi radionuclide generators produced and quality controlled at JRC Karlsruhe or ORNL. The radionuclides obtained from both sites have high radionuclidic and chemical purity, afford high labelling yields and have been found safe for administration to humans by well-trained physicians following established protocols for radiolabeling and quality control.
CLINICAL EXPERIENCE WITH
In view of the currently strongly increasing interest in clinical application of particularly 225 Ac-labeled radioconjugates it is of utmost importance that 225 Ac obtained from sources other than JRC or ORNL is carefully evaluated for purity and safety before administration to humans is considered by physicians. 225 Ac sources of inferior purity may contain potentially toxic radionuclide impurities and may result in low radiochemical yields during radiolabelling. Appropriate purification and validation procedures must be implemented before application to humans. Synthesis and quality control of 225 Ac-labeled ligands for clinical application should be performed only by well-trained staff with experience in handling and analysing 225 Ac and its daughter nuclides. 213 Bi and 225 Ac
Radioimmunotherapy with
The pioneering first-in-human clinical investigations of 213 Bi-labeled antibodies for therapy of leukemia [38, 39] , melanoma [42] [43] [44] and Non-Hodgkins Lymphoma [41] have been reviewed in detail previously [15] . Based on the promising results of two studies investigating the safety and therapeutic efficacy of the 213 Bi-labeled anti-CD33 antibody lintuzumab for therapy of leukemia, clinical studies investigating the 225 Ac labelled analogue are conducted and are summarized in a separate review in this issue.
More recently, a pilot study on the locoregional treatment of bladder cancer (carcinoma in situ) using the 213 Bi-labelled anti-EGFR monoclonal antibody cetuximab has been conducted in collaboration of JRC Karlsruhe and Technical University Munich, Germany [32, 45] . Carcinoma in situ (CIS) is a high-risk bladder cancer due to its tendency to invade neighbouring tissue. Standard treatment options for CIS include transurethral resection and intravesical instillation of Bacillus Calmette-Guerin (BCG). However, a significant fraction of patients eventually becomes unresponsive to BCG treatment and radical cystectomy is typically performed at this stage with an associated drastically reduced quality of life. In this pilot study of targeted alpha therapy, 12 patients scheduled for cystectomy were offered salvage treatment by intravesical instillation of 366-821 MBq 213 Bilabelled anti-EGFR monoclonal antibody. 11 out of 12 patients were treated only once in this pilot study, while one patient was treated twice. The therapy was found to be safe and without any side effects, no activity of 213 Bi was detected outside the bladder. Remarkably, 3 out of 12 patients achieved complete remissions already after one (2/12) or two (1/12) treatments, thus avoiding or delaying cystectomy. These results show that locoregional targeted alpha therapy with 213 Bi-anti-EGFR-MAb is a promising new option for therapy of CIS. Escalation of the administered dose and increasing the number of treatments can be expected to further enhance the therapeutic efficacy and should be investigated in a follow-up study. 213 
Peptide Receptor Alpha Therapy with
Bi and 225 Ac
Targeted peptide receptor alpha therapy with 213 Bi / 225 Ac has to date been clinically tested for treatment of brain tumors, neuroendocrine tumors and prostate cancer. Important advantages of utilizing low molecular weight ligands as targeting vehicles for 213 Bi and 225 Ac include fast tumor uptake and rapid clearance of unbound conjugates from circulation, thus reducing haematological toxicity. Internalizing ligands are particularly advantageous for application in combination with 225 Ac in order to harness the multiple alpha particles emitted in its decay chain.
5.3.
225 Ac-and 213 
Bi-substance P analogues for Glioma Therapy
Peptide receptor alpha therapy of brain tumors has been tested for the first time in two patients as early as 1999 in collaboration of JRC Karlsruhe with University Hospital Basel [46] and subsequently, five more patients were treated in 2007/2008 [47] . The metabolically stabilized substance P analogue DOTA-[Thi 8 ,Met(O 2 ) 11 ]-substance P was used as targeting vector. Substance P is the physiological ligand of the neurokinin-1 (NK-1) receptor that is consistently overex- Ac-PSMA-617 190 [5, 50, 51] pressed in WHO grade II-IV gliomas and that has also been detected on tumour cells infiltrating the intra-and peritumoural vasculature [52] . The low molecular weight peptide (1.8 kDa) has been shown to diffuse rapidly and to be able to localise in remote satellite lesions [46] . In order to overcome the blood-brain barrier and to increase tumor uptake, administration of 213 Bi-[Thi 8 ,Met(O 2 ) 11 ]-substance P was conducted locoregionally via an implanted catheter system with a subcutaneous port. The treatment was found to be safe without severe adverse effects. Remarkably, all 3 early patients diagnosed with grade II gliomas still do not show signs of recurrence or neurological impairments 10 years (2/3) and 18 years (1/3) after therapy.
Based on the promising outcome of these initial clinical experiences with a locoregional injection of 213 Bi-[Thi 8 , Met (O 2 ) 11 ]-substance P, a follow-up investigation was conducted in collaboration of JRC Karlsruhe and Medical University Warsaw [48] . The patient group consisted of 61 patients with grade II to IV gliomas, including primary and secondary recurrent glioblastoma. Patients were treated with up to 14. 11 ]-substance P. The treatment was well tolerated, no severe adverse events were observed. PET/CT imaging demonstrated high retention of the radiolabelled peptide at the tumor site (Fig. 2) , less than 8% I.D. was found in the blood pool within five hours post injection. Fig.  (3) shows magnetic resonance images of a patient with grade III glioma showing excellent response to locoregional treatment with 213 Bi-Substance P analogue. The patient was treated with 8 cycles of 213 Bi-[Thi 8 ,Met(O 2 ) 11 ]-substance P with a cumulative activity of 14.1 GBq in two-month intervals. 44 months after administration of the 8th treatment cycle the patient is in excellent clinical condition. Overall analysis of the therapeutic efficacy in the 61 patients treated to date is ongoing, an interim subgroup analysis indicates prolonged survival times for grade IV patients in comparison to standard treatments [53] .
Widespread glioma cell infiltration into normal adjacent brain areas is the main cause for failure of glioma treatment. Although low molecular weight substance P analogues exhibit relatively rapid diffusion, the short half-life of 213 Bi of 46 min might compromise the delivery of sufficient doses to remote tumor cells. In addition, high activity 225 Ac/ 213 Bi generators required for preparation of therapeutic activities Fig. (2) .
68 Ga-DOTATOC PET/CT image of a patient with recurrent glioblastoma after co-injection of 10 11 ]-substance P. The image taken at 1 hour post injection shows high retention of the radiolabelled compound in the tumor area, with some residual activity remaining in the catheter system. in the multi GBq range are currently still very costly and in limited supply. Therapeutic application of longer-lived 225 Ac could overcome these limitations, and in vitro characterisation of the 225 Ac labelled derivative DOTA-[Thi 8 , Met(O 2 ) 11 ]-substance P showed promising anti-tumor efficacy [54] . Recently an initial dose escalation study investigating the intratumoral/intercavitary injection of 225 ) 11 ]-substance P. The treatment has been well tolerated, analysis of therapeutic efficacy and patient recruitment is ongoing.
5.4.
Bi-DOTATOC for Therapy of Neuroendocrine Tumors
Peptide receptor alpha therapy of neuroendocrine tumors was first investigated clinically in collaboration JRC Karlsruhe and University Hospital Heidelberg. Twenty-five patients with multi-resistant neuroendocrine tumors refractory to therapy with 90 Y-/ 177 Lu-DOTATOC were treated with 213 Bi-DOTATOC. Administration was performed interarterially into the main tumor-feeding vessel in 21 patients, while 4 patients received intravenous injections. Cumulative activities ranging from 2.6 to 21 GBq of 213 Bi-DOTATOC were administered within 1-5 cycles in two-month intervals. Fig. (3) . Magnetic resonance images of a patient with grade III glioma showing excellent response to locoregional treatment with 8 cycles of 213 Bi-Substance P analogue with a cumulative activity of 14.1 GBq (2 months after first therapy (A); 8 months after 8th therapy (B); 33 months after 8 th therapy (C)).
An interim analysis of the first 8 patients showed that chronic kidney toxicity was moderate and hematoxicity was less pronounced than with preceding beta therapies [4] . Remarkably, intravenous administration of 3.3 GBq of 213 Bi-DOTATOC in a patient with extensive bone marrow involvement did not lead to relevant acute haematological side effects, in accordance with the concept of selective tumor cell irradiation with the short-range alpha emitter. Although all patients reported in this investigation were in different challenging situations and had developed resistance against therapy with beta emitters, targeted alpha therapy with 213 Bi-DOTATOC resulted in a high number of long-lasting antitumour responses, including one complete remission. The results of this investigation provided convincing clinical data demonstrating that targeted alpha therapy can offer a valuable additional treatment option to patients refractory to therapy with beta emitters. Furthermore, the study also demonstrated that targeted alpha therapy with short-range alpha radiation is also effective against solid lesions, as impressively illustrated in the SNMMI image of the year 2012 [55] . 213 Bi-DOTATOC can evolve as a promising compound for therapy of neuroendocrine tumors once the supply limitations for high activity 25 Ac/ 213 Bi generators are resolved.
Therapy of neuroendocrine tumors using 225 Ac-DOTATOC was clinically tested in a follow-up investigation with 39 patients with progressive neuroendocrine tumors [56] . The investigation was conducted as an empiric dose escalation to find the Maximum Tolerable Dose (MTD) of a single cycle and fractionation concepts. The MTD of a single cycle 225 Ac-DOTATOC was considered to be 40 MBq. Multiple fractions were tolerated with 25 MBq every 4 months or 18.5 MBq every 2 months. Cumulative activities of 75 MBq were found tolerable in regard to delayed toxicity. The observed radiologic treatment response was without clear preference of a particular fractionation concept. An example of a partial response observed in a patient with a multi-resistant neuroendocrine tumor after two treatment cycles with 16 MBq (1st cycle) and 42 MBq (2nd cycle) 225 Ac-DOTATOC is shown in Fig. (4) .
225 Ac-PSMA-617 for Therapy of Prostate Cancer
The implementation of 225 Ac-PSMA-617 for therapy of metastatic castration-resistant prostate cancer constitutes a major advancement in targeted alpha therapy [57] . 225 Ac-PSMA-617 was first developed and characterised in vitro at JRC Karlsruhe in 2013/2014 and a microwave-assisted protocol for reliable synthesis and quality control of clinical doses was established. Based on the first reports of the promising clinical efficacy of PSMA-617 labelled with the beta emitter 177 Lu and the enhanced cytotoxicity of alpha compared to beta emitters, the concept of combining 225 Ac with the ligand PSMA-617 seemed highly promising. The key features of the pharmacokinetics of PSMA-617, including its fast tumor uptake, high internalization rate, extended tumor retention and rapid clearance of unbound ligand, are highly favourable for combination with an alpha emitter with a halflife of several days and multiple alpha emissions in its decay chain. Clinical testing is currently conducted in collaborations of JRC Karlsruhe with University Hospital Heidelberg, Steve Biko Academic Hospital Pretoria and Technical University Munich.
A dosimetry estimate comparing 225 Ac-PSMA-617 and 213 Bi-PSMA-617 demonstrated that short-lived 213 Bi is an inferior choice for targeted alpha therapy with PSMA-617. 213 Bi-PSMA-617 suffers from higher perfusion-dependent off-target radiation and a longer biological half-life of PSMA-617 in dose-limiting organs than the physical halflife of 213 Bi [58] . To our knowledge, there are no reports to date on the clinical application of 213 Bi-PSMA-617 except for a single case report and hence the subject is not discussed further [59] .
The first report of the remarkable therapeutic efficacy of 225 Ac-PSMA-617 in patients with late-stage metastatic castration-resistant prostate cancer (mCRPC) presented complete remissions observed in two patients in highly challenging situations [5] . To develop a standardized treatment protocol for 225 Ac-PSMA-617 therapy in advanced-stage mCRPC patients, a dosimetry estimate was calculated on the basis of time-activity curves derived from serially obtained 177 Lu-PSMA-617 scans and salvage therapies empirically conducted with 50 to 200 kBq/kg of 225 Ac-PSMA-617 were evaluated retrospectively regarding toxicity and treatment response. For advanced-stage patients, a treatment activity of 100 kBq/kg of 225 Ac-PSMA-617 per cycle repeated every 8 weeks was found to present a reasonable trade-off between toxicity and biochemical response [50] . An interim analysis Fig. (4) . of the efficacy of this treatment protocol was conducted in a retrospectively analysed group of forty patients with mCRPC. Evaluation of PSA and radiological response demonstrated remarkable anti-tumor activity of 225 Ac-PSMA-617 and swimmer-plot analysis indicated the promising duration of tumor-control, especially taking into account the unfavorable prognostic profile of the selected advanced-stage patients. Xerostomia (dry mouth syndrome) was the main reason to discontinue therapy or to refuse additional administrations, indicating that further modifications of the treatment regimen with regard to side effects might be necessary to further enhance the therapeutic range [51] . One of the excellent examples of the therapeutic efficacy of 225 Ac-PSMA-617 in a patient with mCRPC that was progressive under conventional therapy is shown in Fig. (5) . The patient was treated at Steve Biko Academic Hospital, Pretoria, with two cycles of 225 Ac-PSMA-617 with a cumulative activity of 14 MBq. Restaging with 68 Ga-PSMA PET/CT after 5 months showed a remarkable molecular imaging response. This patient also demonstrated a biochemical response with a decrease in PSA level from 1,301 to <0.05 ng/mL. Fig. (5) . Excellent response to therapy after 2 cycles of 225 Ac-PSMA-617 demonstrated by 68 Ga-PSMA-11 PET/CT images of patient with metastatic castration-resistant prostate cancer before (left panel) and after (right panel), with decrease in serum PSA level from 1,301 to <0.05 ng/mL. The patient was treated at Steve Biko Academic Hospital, Pretoria, with two cycles of 225 Ac-PSMA-617 with a cumulative activity of 14 MBq.
CONCLUSION
The recent reports on the remarkable therapeutic efficacy of 225 Ac-PSMA-617 for the therapy of mCRPC have significantly sparked interest in the clinical application of targeted alpha therapy. The implementation of 225 Ac-PSMA-617 does not only provide a promising therapeutic option for the second most frequent cancer in men, but also successfully underlines the significant potential of the concept of targeted alpha therapy as such. The clinical data recently obtained on targeted alpha therapy of neuroendocrine tumors and prostate cancer convincingly show that therapy with alpha emitters can overcome resistance to therapy with conventional drugs and also with beta emitters and can offer a valuable additional treatment option to patients that have failed established treatments. The combination of 225 Ac or 213 Bi with low molecular weight peptide ligands seems particularly promising due to the favourable pharmacokinetics of these ligands. The clinical experience with locoregional treatment of glioma with 225 Ac-and 213 Bi-labelled substance P analogues is promising and needs to be validated further. The intravesical therapy of bladder cancer with 213 Bi-anti-EGFR MAb is an intriguing approach that certainly deserves further study. For all these promising novel approaches formal clinical studies are highly warranted to compare the safety and efficacy against approved therapies under controlled conditions.
To satisfy the increased clinical demand for 225 Ac, accelerator driven production routes, preferably based on proton irradiation of 226 Ra in medium energy cyclotrons, should be rapidly implemented. In general, the safety of 225 Ac obtained from alternative sources should be carefully evaluated before its administration to humans is considered. 225 Ac and 213 Bi are highly cytotoxic radionuclides that can provide remarkable benefit to cancer patients. Their clinical application should be conducted by well-trained physicians, following established protocols and guidelines for radiolabeling and quality control.
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